Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein

Pharmacotherapy

Volumn 25, Issue 6, 2005, Pages 779-789

  Joy, Melanie S ^a   Nickeleit, Volker ^a   Hogan, Susan L ^a   Thompson, Bawana D ^a   Finn, William F ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Calcineurin inhibitors; Drug transporters; Nephrotoxicity; P glycoprotein expression; Renal biopsy; Solid organ transplants

Indexed keywords

CALCINEURIN INHIBITOR; CASPASE 3; CYCLOSPORIN; GLYCOPROTEIN P; TACROLIMUS;

ADULT; APOPTOSIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; FEMALE; GLOMERULUS FILTRATION RATE; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LOGISTIC REGRESSION ANALYSIS; MALE; MEDICAL RECORD; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PROTEIN EXPRESSION; PROTEINURIA; RETROSPECTIVE STUDY;

ADULT; CALCINEURIN; CASE-CONTROL STUDIES; COLORING AGENTS; CYCLOSPORINE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY DISEASES; KIDNEY TRANSPLANTATION; LOGISTIC MODELS; MALE; P-GLYCOPROTEIN; TACROLIMUS;

EID: 19444367600     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.2005.25.6.779     Document Type: Article

References (40)

1. Organ Procurement and Transplantation Network. The U.S. organ procurement and transplantation network/scientific registry of transplant recipients annual report. Available from http://www.optn.org/AR2004. Accessed August 9, 2004.
2. Gonwa TA, Morris CA, Goldstein RM, Husberg BS, Klintmalm GB. Long-term survival and renal function following liver transplantation in patients with and without hepatorenal syndrome: experience in 300 patients. Transplantation 1991;51:428-30.
3. Zietse R, Balk AH, Vd Dorpel MA, Meeter K, Bos E, Weimar W. Time course of the decline in renal function in cyclosporine-treated heart transplant recipients. Am J Nephrol 1994;14:1-5.
4. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326-33.
5. Mihatsch MJ, Thiel G, Ryffel B. Histopathology of cyclosporine nephrotoxicity. Transplant Proc 1988;20(suppl 3):759-71.
6. Mihatsch MJ, Helmchen U, Casanova P, et al. Kidney biopsy findings in cyclosporine-treated patients with insulin-dependent diabetes mellitus. Klin Wochenschr 1991;69:354-9.
7. Gudat F, Mihatsch MJ, Ryffel B, Thiel G. Cyclosporine nephropathy. In: Tisher CC, ed. Renal pathology with clinical and functional correlations. Philadelphia: J.B. Lippincott Company; 1994:1641-82.
8. Burdmann EA, Andoh TF, Yu L, Bennett WM. Cyclosporine nephroloxicity. Semin Nephrol 2003;23:465-76.
9. Morozumi K, Takeda A, Uchida K, Mihatsch MJ. Cyclosporine nephroloxicity: how does it affect renal allograft function and transplant morphology? Transplant Proc 2004;36(suppl 2):S251-6.
10. Ernest S, Bello-Reuss E. P-glycoprotein functions and substrates: possible roles of MDR1 gene in the kidney. Kidney Int Suppl 1998;65:S11-17.
11. Tsuruoka S, Sugimoto KI, Fujimura A, Imai M, Asano Y, Muto S. P-glycoprotein-mediated drug secretion in mouse proximal tubule perfused in vitro. J Am Soc Nephrol 2001;12:177-81.
12. Ernest S, Rajaraman S, Megyesi J, Bello-Reuss EN. Expression of MDR1 (multidrug resistance) gene and its protein in normal human kidney. Nephron 1997;77:284-9.
13. Hauser IA, Koziolek M, Hopfer U, Thevenod F. Therapeutic concentrations of cyclosporine A, but not FK506, increase P-glycoprotein expression in endothelial and renal tubule cells. Kidney Int 1998;54:1139-49.
14. Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprolein transports cyclosporin A and FK506. J Biol Chem 1993;268:6077-80.
15. Drach J, Gsur A, Hamilton G, et al. Involvement of P-glycoprotein in the transmembrane transport of interleukin-2 (1L-2), IL-4, and interferon-gamma in normal human T lymphocytes. Blood 1996;88:1747-54.
16. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD. Human MDR 1 protein overexpression delays the apoptolic cascade in Chinese hamster ovary fibroblasts. Biochemistry 1997;36:11169-78.
17. Johnstone RW, Fuefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter p-glycoprotein? Trends Biochem Sci 2001;25:1-6.
18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
19. Koziolek MJ, Riess R, Geiger H, Thevenod F, Hauser IA. Expression of multidrug resistance P-glycoprotein in kidney allografts from cyclosporine A-treated patients. Kidney Int 2001;60:156-66.
20. Ernest S, Bello-Reuss E. Expression and function of P-glycoprotein in a mouse kidney cell line. Am J Physiol 1995;269(2 pt 1):C323-33.
21. Bello-Reuss E, Ernest S. Expression and function of P-glycoprotein in human mesangial cells. Am J Physiol 1994;267(5 pt 1):C1351-8.
22. Del Moral RG, Andujar M, Ramirez C, et al. Chronic cyclosporin A nephrotoxicity, P-glycoprotein overexpression, and relalionships wilh intrarenal angiotensin 11 deposits. Am J Pathol 1997;151:1705-14.
23. Del Moral RG, Olmo A, Osuna A, et al. Role of P-glycoprotein in chronic cyclosporine nephrotoxicity and its relationship to intrarenal angiotensin II deposits. Transplant Proc 1998;30:2014-6.
24. Del Moral RG, Olmo A, Aguilar M, O'valle F. P-glycoprotein: a new mechanism to control drug-induced nephrotoxicity. Exp Nephrol 1998;6:89-97.
25. Garcia Del Moral R, O'valle F, Andujar M, et al. Relationship between P-glycoprotein expression and cyclosporin A in kidney: an immunohistological and cell culture study. Am J Pathol 1995;146:398-408.
26. Bennett WM, Demattos A, Meyer MM, Andoh T, Barry JM. Chronic cyclosporine nephropathy: the Achilles heel of immunosuppressive therapy. Kidney Int 1996;50:1089-100.
27. Sonneveld P, Durie BG, Lokhorst HM, et al. Modulation of multidrug-resistant multiple myeloma by cyclosporin. The leukaemia group of the EORTC and the HOVON. Lancet 1992;340:255-9.
28. Huang ZH, Murakami T, Okochi A, Yumoto R, Nagai J, Takano M. Expression and function of P-glycoprotein in rats with glycerol-indutcd acute renal failure. Eur J Pharmacol 2000;406:453-60.
29. Rana A, Sathyanarayana P, Lieberthal W. Role of apoptosis of renal tubular cells in acute renal failure: therapeutic implications. Apoptosis 2001;6:83-102.
30. Thevenod F, Friedmann JM, Kalsen AD, Hauser IA. Upregulation of multidrug resistance P-glycoprotein via nuclear factor-K B activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis. J Biol Chem 2000;275:1887-96.
31. Li C, Lim S, Sun B, et al. Expression of apoptosis-related factors in chronic cyclosporine nephrotoxicity after cyclosporinc withdrawal. Acta Pharmacol Sin 2004;25:401-11.
32. Hortelano S, Castilla M, Torres AM, Tejedor A, Bosca L Potentiation by nitric oxide of cyclosporin A and FK506-induced apoplosis in renal proximal tubule cells. J Am Soc Nephrol 2000;11:2315-23.
33. Thomas SE, Andoh TF, Pichler RH, et al. Accelerated apoptosis characterizes cyclosporine-associated interstitial fibrosis. Kidney Int 1998;53:897-908.
34. Ortiz A, Lorz C, Catalan M, Coca S, Egido J. Cyclosporine A induces apoptosis in murine tubular epithelial cells: role of caspases. Kidney Int 1998;68(suppl):S25-9.
35. Amore A, Emancipator SN, Cirina P, et al. Nitric oxide mediates cyclosporine-induced apoptosis in cultured renal cells. Kidney Int 2000;57:1549-59.
36. Sakaeda T, Nakamura T, Hirai M, et al. MDR1 up-regulated by apoptotic stimuli suppresses apoptotic signaling. Pharm Res 2002;19:1323-9.
37. Smyth MJ, Krasovskis E, Sutton VR, Johnstone RW. The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoplosis. Proc Natl Acad Sci USA 1998;95:7024-9.
38. Johnstone RW, Cretney E, Smyth MJ. P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death. Blood 1999;93:1075-85.
39. Nunez G, Benedict MA, Hu Y, Inohara N. Caspases: the proleases of the apoptolic pathway. Oncogene 1998;17:3237-45.
40. Mukerjee N, Mcginnis KM, Gnegy ME, Wang KK. Caspase-mediated calcineurin activation contributes to 1L-2 release during T cell activation. Biochem Biophys Res Commun 2001;285:1192-9.